Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01538862 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients With Dystrophic Epidermolysis Bullosa
A Phase 2 study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT01538862 is a Phase 2 study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 7 participants.
The verdict
NCT01538862, a Phase 2 study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is a feasibility study to see if Granulocyte Colony Stimulating Factor (GCSF) is effective as a treatment of Dystrophic Epidermolysis Bullosa (EB). Patients will receive one course of treatment with the study drug. The course will be 7 days in length. After receiving GCSF, patients will be followed at 7 and 30 days following the discontinuation of the drug. Thirty day follow up can be done via telephone communication with the patient or family.
Interventions
- DRUG Granulocyte Colony Stimulating Factor (GCSF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2012-02 |
| Est. Completion | 2014-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01538862
The ClinicalTrials.gov registry entry for NCT01538862 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Granulocyte Colony Stimulating Factor (GCSF) is the first listed.
NCT01538862 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01538862 about?
NCT01538862 is a clinical study titled "Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients With Dystrophic Epidermolysis Bullosa". This is a feasibility study to see if Granulocyte Colony Stimulating Factor (GCSF) is effective as a treatment of Dystrophic Epidermolysis Bullosa (EB). Patients will receive one course of treatment with the study drug. The course will be 7 days in length. After receiving GCSF, patients will be foll...
What is the current status of trial NCT01538862?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2012-02. Estimated completion is 2014-11.
What interventions are being tested in trial NCT01538862?
The interventions under investigation include: Granulocyte Colony Stimulating Factor (GCSF) (DRUG).
Who is sponsoring clinical trial NCT01538862?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.